Good morning ladies and gentlemen, my name is James McBrayer, the Managing Director of Cyclopharm.
Slide 7 – Financial Highlights
To begin, I would like to provide a review of our financial performance in 2020. During the year, we reported record Group Sales of $14.7 million, up 4.2% from the previous year, and buoyed by $2.2 million of new third-party distribution revenue. This new thirdparty sales growth more than offset the negative revenue impact of COVID-19 across the business. These results places the Company in a strong financial position as we return to more normal trading conditions and growth, post-COVID.
For more information, download the attached PDF.
Download this document
